Sean McSweeney

Mr. Sean McSweeney

University of Minnesota Medical School
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2020 in Medical Image Analysis
Verified
Journal Article
Closed access
NHNicholas Heller
Nicholas Heller
FIFabian Isensee
Fabian Isensee
KMKlaus H. Maier-Hein
Klaus H. Maier-Hein
XHXiaoshuai Hou
Xiaoshuai Hou
CXChunmei Xie
Chunmei Xie
CWChristopher J. Weight
Christopher J. Weight

1 October 2020 in Journal of Endourology
Verified
Journal Article
Closed access
BSBethany Stai
Bethany Stai
NHNicholas Heller
Nicholas Heller
SMSean McSweeney
Sean McSweeney
JRJack Rickman
Jack Rickman
PBPaul Blake
Paul Blake
CWChristopher J. Weight
Christopher J. Weight
Objective: To understand better the public perception and comprehension of medical technology such as artificial intelligence (AI) and robotic surgery. In addition to this, to identify sensitivity to their use to ensure acceptability and quality of counseling. Subjects and Methods: A survey was conducted on a convenience sample of visitors to the MN Minnesota State Fair ( n = 264). Participants were randomized to receive one of two similar surveys. In the first, a diagnosis was made by a physician and in the second by an AI application to compare confidence in human and computer-based diagnosis. Results: The median age of participants was 45 (interquartile range 28–59), 58% were female ( n = 154) vs 42% male ( n = 110), 69% had completed at least a bachelor's degree, 88% were Caucasian ( n = 233) vs 12% ethnic minorities ( n = 31) and were from 12 states, mostly from the Upper Midwest. Participants had nearly equal trust in AI vs physician diagnoses. However, they were significantly more likely to trust an AI diagnosis of cancer over a doctor's diagnosis when responding to the version of the survey that suggested that an AI could make medical diagnoses ( p = 9.32e-06). Though 55% of respondents ( n = 145) reported that they were uncomfortable with automated robotic surgery, the majority of the individuals surveyed (88%) mistakenly believed that partially autonomous surgery was already happening. Almost all (94%, n = 249) stated that they would be willing to pay for a review of medical imaging by an AI if available. Conclusion: Most participants express confidence in AI providing medical diagnoses, sometimes even over human physicians. Participants generally express concern with surgical AI, but they mistakenly believe that it is already being performed. As AI applications increase in medical practice, health care providers should be cognizant of the potential amount of misinformation and sensitivity that patients have to how such technology is represented.

26 October 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JVJordan E. Vellky
Jordan E. Vellky
SMSean McSweeney
Sean McSweeney
EREmily A. Ricke
Emily A. Ricke
WRWilliam Ricke
William Ricke
Significance: Little is known regarding the mechanisms involved in loss of androgen receptor (AR) function in the development of castration resistance. Recently, the clinical use of new potent AR therapies has led to the emergence of a new lethal subtype of castration-resistant prostate cancer (CRPC) lacking AR protein and signaling, termed ARL/negative CRPC. We discovered that DDX3 (DEAD-box helicase 3 X-linked) is a key repressor of AR protein translation—a mechanism that leads to development of castration resistance. Inhibition of DDX3 in ARL/negative CRPC promotes the expression of AR protein/signaling and hence sensitivity to hormone therapy. These data provide a molecular mechanism for hormone action and describe a synthetic lethality approach to the clinical treatment of therapy-resistant diseases such as CRPC.

12 May 2022 in eLife
Verified
Journal Article
Open access
JHJustin Hwang
Justin Hwang
RARand Arafeh
Rand Arafeh
JSJi-Heui Seo
Ji-Heui Seo
SBSylvan C Baca
Sylvan C Baca
MLMegan Ludwig
Megan Ludwig
WHWilliam C Hahn
William C Hahn
Metastatic castration-resistant prostate cancers (mCRPCs) are treated with therapies that antagonize the androgen receptor (AR). Nearly all patients develop resistance to AR-targeted therapies (ARTs). Our previous work identified CREB5 as an upregulated target gene in human mCRPC that promoted resistance to all clinically approved ART. The mechanisms by which CREB5 promotes progression of mCRPC or other cancers remains elusive. Integrating ChIP-seq and rapid immunoprecipitation and mass spectroscopy of endogenous proteins, we report that cells overexpressing CREB5 demonstrate extensive reprogramming of nuclear protein–protein interactions in response to the ART agent enzalutamide. Specifically, CREB5 physically interacts with AR, the pioneering actor FOXA1, and other known co-factors of AR and FOXA1 at transcription regulatory elements recently found to be active in mCRPC patients. We identified a subset of CREB5/FOXA1 co-interacting nuclear factors that have critical functions for AR transcription (GRHL2, HOXB13) while others (TBX3, NFIC) regulated cell viability and ART resistance and were amplified or overexpressed in mCRPC. Upon examining the nuclear protein interactions and the impact of CREB5 expression on the mCRPC patient transcriptome, we found that CREB5 was associated with Wnt signaling and epithelial to mesenchymal transitions, implicating these pathways in CREB5/FOXA1-mediated ART resistance. Overall, these observations define the molecular interactions among CREB5, FOXA1, and pathways that promote ART resistance.

4 January 2022 in Frontiers in Digital Health
Verified
Journal Article
Open access
NSNiranjan Sathianathen
Niranjan Sathianathen
NHNicholas Heller
Nicholas Heller
RTResha Tejpaul
Resha Tejpaul
BSBethany Stai
Bethany Stai
AKArveen Kalapara
Arveen Kalapara
CWChristopher J. Weight
Christopher J. Weight
Purpose: Clinicians rely on imaging features to calculate complexity of renal masses based on validated scoring systems. These scoring methods are labor-intensive and are subjected to interobserver variability. Artificial intelligence has been increasingly utilized by the medical community to solve such issues. However, developing reliable algorithms is usually time-consuming and costly. We created an international community-driven competition (KiTS19) to develop and identify the best system for automatic segmentation of kidneys and kidney tumors in contrast CT and report the results.Methods: A training and test set of CT scans that was manually annotated by trained individuals were generated from consecutive patients undergoing renal surgery for whom demographic, clinical and outcome data were available. The KiTS19 Challenge was a machine learning competition hosted on grand-challenge.org in conjunction with an international conference. Teams were given 3 months to develop their algorithm using a full-annotated training set of images and an unannotated test set was released for 2 weeks from which average Sørensen-Dice coefficient between kidney and tumor regions were calculated across all 90 test cases.Results: There were 100 valid submissions that were based on deep neural networks but there were differences in pre-processing strategies, architectural details, and training procedures. The winning team scored a 0.974 kidney Dice and a 0.851 tumor Dice resulting in 0.912 composite score. Automatic segmentation of the kidney by the participating teams performed comparably to expert manual segmentation but was less reliable when segmenting the tumor.Conclusion: Rapid advancement in automated semantic segmentation of kidney lesions is possible with relatively high accuracy when the data is released publicly, and participation is incentivized. We hope that our findings will encourage further research that would enable the potential of adopting AI into the medical field.

19 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
APAnna Prizment
Anna Prizment
SMSean McSweeney
Sean McSweeney
NPNathan Pankratz
Nathan Pankratz
CJCorinne E. Joshu
Corinne E. Joshu
JHJustin Hwang
Justin Hwang
CRCharles Ryan
Charles Ryan
Genetic variations in androgen metabolism may influence prostate cancer (PC) prognosis. Clinical studies consistently linked PC prognosis with four single nucleotide polymorphisms (SNPs) in the critical androgen-regulating genes: 3-beta-hydroxysteroid dehydrogenase (HSD3B1) rs1047303, 5-alpha-reductase 2 (SRD5A2) rs523349, and solute carrier organic ion (SLCO2B1) rs1789693 and rs12422149. We tested the association of four androgen-regulating SNPs, individually and combined, with PC-specific mortality in the ARIC population-based prospective cohort. Men diagnosed with PC (N = 622; 79% White, 21% Black) were followed for death (N = 350) including PC death (N = 74). Cox proportional hazards regression was used to estimate hazard ratios (HR) and 95%CI adjusting for center, age, stage, and grade at diagnosis using separate hazards for races. A priori genetic risk score (GRS) was created as the unweighted sum of risk alleles in the four pre-selected SNPs. The gain-of-function rs1047303C allele was associated PC-specific mortality among men with metastatic PC at diagnosis (HR = 4.89 per risk allele, p = 0.01). Higher GRS was associated with PC-specific mortality (per risk allele: HR = 1.26, p = 0.03). We confirmed that the gain-of-function allele in HSD3B1 rs1047303 is associated with greater PC mortality in men with metastatic disease. Additionally, our findings suggest a cumulative effect of androgen-regulating genes on PC-specific mortality; however, further validation is required.